FDA approval for Abbott’s Aveir VR leadless pacemaker

1791

Abbott has announced that the US Food and Drug Administration (FDA) has approved the Aveir single-chamber (VR) leadless pacemaker for the treatment of patients in the USA with slow heart rhythms. This marks significant advancement for patient care and brings new, never-before-seen features to patients and their physicians, Abbott said in a press release.

The Aveir leadless pacemaker is implanted directly inside the heart’s right ventricle via a minimally invasive procedure to treat slower-than-normal heart rates. Unlike traditional pacemakers, leadless pacemakers do not require an incision in the chest to implant the device or cardiac leads to deliver therapy.

In its press release, Abbott states that device has a unique mapping capability designed to allow physicians to measure electrical signals within the heart and determine the correct placement of the device before final implantation. The company adds that it has an increased projected battery life that can be up to two times longer than other currently commercially available leadless pacemakers when using International Organization for Standardization (ISO) standard settings. In addition, the device is the only leadless pacemaker designed to be retrieved if therapy needs evolve, Abbott adds.

“The Aveir leadless pacemaker offers an exciting option for the treatment of people with cardiac arrhythmias. Leadless pacemakers address known complications associated with traditional pacemakers. In addition, the Aveir leadless pacemaker brings unique innovations we have been seeking, such as the ability to ensure electrical performance before we commit to placement,” said Rahul Doshi (Honor Health, Scottsdale, USA). “Abbott’s leadless pacemaker addresses the need for a single-chamber device that accommodates any therapy path for a patient through Aveir’s retrieval capability and extended battery longevity.”

This approval is supported by data from the global LEADLESS II phase 2 investigational device exemption (IDE) study evaluating Aveir VR in patients with certain abnormal heart rhythms. The results showed the device met its pre-specified primary endpoints. The findings were presented at the annual Scientific Sessions of the Asia Pacific Heart Rhythm Society (APHRS 2021, 11–14 November, Suzhou, China) in November 2021 and simultaneously published in the Journal of the American College of Cardiology: Clinical Electrophysiology.

“The Aveir VR leadless pacemaker was designed to make the implantation and retrieval processes as seamless as possible for physicians and provide improvements over existing options,” said Randel Woodgrift, senior vice president, Cardiac Rhythm Management, Abbott. “Our goal is to continue to build on the success of Aveir to provide more first-of-their-kind products in the future, revolutionising how abnormal heart rhythms are treated.”


LEAVE A REPLY

Please enter your comment!
Please enter your name here